clinical trial · NCT05766748
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic CancerAzeliragon
brief summary
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
started
Jun 1, 2023
primary completion
Feb 1, 2025
completion
May 1, 2025
last updated
Jun 14, 2024
official title
A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol